Inogen Announces Participation in the 2018 Stifel Healthcare Conference

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 2018 Stifel Healthcare Conference in New York City.

Inogen’s President and CEO, Scott Wilkinson and CFO, Alison Bauerlein are scheduled to present on Tuesday, November 13, 2018 at 2:45 p.m. ET at the 2018 Stifel Healthcare Conference. Interested parties can access the live audio webcast from the Events section of the Investor Relations page on the Inogen website at www.inogen.com. A webcast replay will be available approximately one hour after the conclusion of the live presentation and will remain available for 90 days.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005823/en/

Inogen, Inc.
Investor Relations Contact:
Matt Bacso, CFA
805-879-8205
or
Media Contact:
Byron Myers
805-562-0503

Source: Inogen, Inc.

You May Also Be Interested In

• Monster Energy's Max Alran Takes First Place in Downhill Mountain Bike Race at the 2026 WHOOP UCI Mountain Bike World Series Les Gets
• Sergio V. Crowley Publishes Operations Research Framework for Industrial Capital Deployment
• Best Crypto Presale: AlphaPepe at $0.02789 Keeps the $1 Roadmap Trade Alive With Public Trading Still Ahead